Onconova Therapeutics, a biotech focused on developing novel small molecule drug candidates for cancer, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The Newtown, PA-based company, which was founded in 1998, booked $47 million in revenue for the 12 months ended 3/31/2013, primarily from its collaboration agreements with Baxter and SymBio. Onconova Therapeutics plans to list on the NASDAQ under the symbol ONTX. It initially filed confidentially on 5/3/2013. Citi and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
